These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

444 related articles for article (PubMed ID: 36319536)

  • 1. Simulation of lipid-lowering therapy (LLT) intensification in very high-risk patients with atherosclerotic cardiovascular disease.
    Gu J; Sanchez RJ; Chauhan A; Fazio S; Rosenson RS
    J Clin Lipidol; 2022; 16(6):901-905. PubMed ID: 36319536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simulation of Lipid-Lowering Therapy Intensification in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Khan I; Klimchak AC; Reynolds MR; Sanchez RJ; Sasiela WJ
    JAMA Cardiol; 2017 Sep; 2(9):959-966. PubMed ID: 28768335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulation of the Impact of Statin Intolerance on the Need for Ezetimibe and/or Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor for Meeting Low-Density Lipoprotein Cholesterol Goals in a Population With Atherosclerotic Cardiovascular Disease.
    Cannon CP; Sanchez RJ; Klimchak AC; Khan I; Sasiela WJ; Reynolds MR; Rosenson RS
    Am J Cardiol; 2019 Apr; 123(8):1202-1207. PubMed ID: 30736965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Variation in Lipid-Lowering Therapy Use in Patients With Low-Density Lipoprotein Cholesterol ≥190 mg/dL: Insights From the National Cardiovascular Data Registry-Practice Innovation and Clinical Excellence Registry.
    Virani SS; Kennedy KF; Akeroyd JM; Morris PB; Bittner VA; Masoudi FA; Stone NJ; Petersen LA; Ballantyne CM
    Circ Cardiovasc Qual Outcomes; 2018 May; 11(5):e004652. PubMed ID: 29748356
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simulation study on LDL cholesterol target attainment, treatment costs, and ASCVD events with bempedoic acid in patients at high and very-high cardiovascular risk.
    Katzmann JL; Becker C; Bilitou A; Laufs U
    PLoS One; 2022; 17(10):e0276898. PubMed ID: 36301892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
    Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
    BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pragmatic Trial of Messaging to Providers About Treatment of Hyperlipidemia (PROMPT-LIPID): A Randomized Clinical Trial.
    Shah NN; Ghazi L; Yamamoto Y; Kumar S; Martin M; Simonov M; Riello Iii RJ; Faridi KF; Ahmad T; Wilson FP; Desai NR
    Circ Cardiovasc Qual Outcomes; 2024 May; 17(5):e010335. PubMed ID: 38634282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hypercholesterolemia and cardiovascular risk].
    Sinning D; Landmesser U
    Dtsch Med Wochenschr; 2023 Aug; 148(16):1025-1032. PubMed ID: 37541292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent Updates on the Use of PCSK9 Inhibitors in Patients with Atherosclerotic Cardiovascular Disease.
    Dixon DL; Pamulapati LG; Bucheit JD; Sisson EM; Smith SR; Kim CJ; Wohlford GF; Pozen J
    Curr Atheroscler Rep; 2019 Mar; 21(5):16. PubMed ID: 30877491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uptake of non-statin lipid-lowering therapies for secondary prevention in community practice.
    Bradley CK; Kolkailah AA; Shah NP; Page CB; Peterson ED; Navar AM
    J Clin Lipidol; 2023; 17(3):412-414. PubMed ID: 37029056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical characteristics and treatment patterns in patients with atherosclerotic cardiovascular disease with hypercholesterolemia: a retrospective analysis of a large US real-world database cohort.
    Lahoz R; Seshagiri D; Electricwala B; Achouba A; Ding Y; Heo JH; Cristino J; Studer R
    Curr Med Res Opin; 2024 Jan; 40(1):15-25. PubMed ID: 37941428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclisiran: A Review in Hypercholesterolemia.
    Frampton JE
    Am J Cardiovasc Drugs; 2023 Mar; 23(2):219-230. PubMed ID: 36869996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of Statins, Ezetimibe, PCSK9-Inhibitors, Inclisiran, and Icosapent Ethyl on Platelet Function.
    Di Costanzo A; Indolfi C; Sorrentino S; Esposito G; Spaccarotella CAM
    Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511498
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the potential long-term survival benefit of evinacumab treatment vs. standard of care in patients with homozygous familial hypercholesterolaemia.
    Gu J; Kuznik A; Quon P; Chauhan A; Sravya TS; Raal FJ
    Eur J Prev Cardiol; 2023 Nov; 30(17):1874-1880. PubMed ID: 37314419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of lipid-lowering therapies in patients with chronic kidney disease and atherosclerotic cardiovascular disease: 2-year results from Getting to an imprOved Understanding of Low-Density lipoprotein cholesterol and dyslipidemia management (GOULD).
    Shaik A; Kosiborod M; de Lemos JA; Gao Q; Mues KE; Alam S; Bhatt DL; Cannon CP; Ballantyne CM; Rosenson RS;
    Clin Cardiol; 2022 Dec; 45(12):1303-1310. PubMed ID: 36124341
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Barriers to prescribing proprotein convertase subtilisin-kexin type 9 inhibitors after coronary revascularisation.
    Nguy J; Hitchen SA; Lan NSR; Dwivedi G; Larbalestier R; Yeap BB; Fegan PG
    Intern Med J; 2023 Jun; 53(6):994-1001. PubMed ID: 35112773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation of bempedoic acid and ezetimibe in the lipid-lowering treatment pathway in Austria using the contemporary SANTORINI cohort of high and very high risk patients.
    Toplak H; Bilitou A; Alber H; Auer J; Clodi M; Ebenbichler C; Fließer-Görzer E; Gelsinger C; Hanusch U; Ludvik B; Maca T; Schober A; Sock R; Speidl WS; Stulnig TM; Weitgasser R; Zirlik A; Koch M; Wienerroither S; Wolowacz SE; Diamand F; Catapano AL
    Wien Klin Wochenschr; 2023 Jul; 135(13-14):364-374. PubMed ID: 37286910
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid-lowering treatment up to one year after acute coronary syndrome: guidance from a French expert panel for the implementation of guidelines in practice.
    Sabouret P; Puymirat E; Kownator S; Abdennbi K; Lebeau F; Meltz M; Angoulvant D; Schiele F
    Panminerva Med; 2023 Jun; 65(2):244-249. PubMed ID: 36222543
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors.
    Pinsdorf D; Messiha D; Petrikhovich O; Bahar M; Steinmetz M; Mahabadi AA; Dykun I; Lortz J; Rassaf T; Rammos C
    J Clin Lipidol; 2023; 17(4):504-511. PubMed ID: 37271601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Do we need new lipid-lowering agents in the era of PCSK9 inhibitors? Recent advances.
    Atar D; Langslet G; Tonstad S
    Kardiol Pol; 2022; 80(7-8):741-749. PubMed ID: 35521719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.